The current state of immunotherapy for gliomas: an eye toward the future
The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier...
Gespeichert in:
| Veröffentlicht in: | Journal of neurosurgery 2019-09, Vol.131 (3), p.657 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 657 |
| container_title | Journal of neurosurgery |
| container_volume | 131 |
| creator | Fecci, Peter E Sampson, John H |
| description | The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed. |
| doi_str_mv | 10.3171/2019.5.JNS181762 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2283316661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2283316661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c230t-a3cc99e40ec1694d8d89d66b52f8c478b366b4b20ef33500fa49e1c5cba678ed3</originalsourceid><addsrcrecordid>eNpNjztPwzAYRS0EoqWwMyGPLCl-xbHZUAUUVMFAmSPH-UyDkrj4IdR_TyWKxHTvcHR0L0KXlMw5regNI1TPy_nzyxtVtJLsCE2p5rwgUvPjf32CzmL8JIRKIdkpmnAqKi6lmqLlegPY5hBgTDgmkwB7h7thyKNPGwhmu8POB_zRd34w8RabEcMOcPLfJrR4j2CXUw5wjk6c6SNcHHKG3h_u14tlsXp9fFrcrQrLOEmF4dZqDYKApVKLVrVKt1I2JXPKiko1-1mNaBgBx3lJiDNCA7WlbYysFLR8hq5_vdvgvzLEVA9dtND3ZgSfY82Y4pxKKekevTqguRmgrbehG0zY1X_v-Q_o9VxH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2283316661</pqid></control><display><type>article</type><title>The current state of immunotherapy for gliomas: an eye toward the future</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Fecci, Peter E ; Sampson, John H</creator><creatorcontrib>Fecci, Peter E ; Sampson, John H</creatorcontrib><description>The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.</description><identifier>ISSN: 1933-0693</identifier><identifier>EISSN: 1933-0693</identifier><identifier>DOI: 10.3171/2019.5.JNS181762</identifier><identifier>PMID: 31473668</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Brain Neoplasms - therapy ; Cancer Vaccines ; Glioblastoma - therapy ; Glioma - therapy ; Humans ; Immunotherapy - trends ; T-Lymphocytes - immunology</subject><ispartof>Journal of neurosurgery, 2019-09, Vol.131 (3), p.657</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c230t-a3cc99e40ec1694d8d89d66b52f8c478b366b4b20ef33500fa49e1c5cba678ed3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31473668$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fecci, Peter E</creatorcontrib><creatorcontrib>Sampson, John H</creatorcontrib><title>The current state of immunotherapy for gliomas: an eye toward the future</title><title>Journal of neurosurgery</title><addtitle>J Neurosurg</addtitle><description>The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.</description><subject>Animals</subject><subject>Brain Neoplasms - therapy</subject><subject>Cancer Vaccines</subject><subject>Glioblastoma - therapy</subject><subject>Glioma - therapy</subject><subject>Humans</subject><subject>Immunotherapy - trends</subject><subject>T-Lymphocytes - immunology</subject><issn>1933-0693</issn><issn>1933-0693</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNjztPwzAYRS0EoqWwMyGPLCl-xbHZUAUUVMFAmSPH-UyDkrj4IdR_TyWKxHTvcHR0L0KXlMw5regNI1TPy_nzyxtVtJLsCE2p5rwgUvPjf32CzmL8JIRKIdkpmnAqKi6lmqLlegPY5hBgTDgmkwB7h7thyKNPGwhmu8POB_zRd34w8RabEcMOcPLfJrR4j2CXUw5wjk6c6SNcHHKG3h_u14tlsXp9fFrcrQrLOEmF4dZqDYKApVKLVrVKt1I2JXPKiko1-1mNaBgBx3lJiDNCA7WlbYysFLR8hq5_vdvgvzLEVA9dtND3ZgSfY82Y4pxKKekevTqguRmgrbehG0zY1X_v-Q_o9VxH</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Fecci, Peter E</creator><creator>Sampson, John H</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20190901</creationdate><title>The current state of immunotherapy for gliomas: an eye toward the future</title><author>Fecci, Peter E ; Sampson, John H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c230t-a3cc99e40ec1694d8d89d66b52f8c478b366b4b20ef33500fa49e1c5cba678ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Brain Neoplasms - therapy</topic><topic>Cancer Vaccines</topic><topic>Glioblastoma - therapy</topic><topic>Glioma - therapy</topic><topic>Humans</topic><topic>Immunotherapy - trends</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fecci, Peter E</creatorcontrib><creatorcontrib>Sampson, John H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fecci, Peter E</au><au>Sampson, John H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The current state of immunotherapy for gliomas: an eye toward the future</atitle><jtitle>Journal of neurosurgery</jtitle><addtitle>J Neurosurg</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>131</volume><issue>3</issue><spage>657</spage><pages>657-</pages><issn>1933-0693</issn><eissn>1933-0693</eissn><abstract>The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.</abstract><cop>United States</cop><pmid>31473668</pmid><doi>10.3171/2019.5.JNS181762</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1933-0693 |
| ispartof | Journal of neurosurgery, 2019-09, Vol.131 (3), p.657 |
| issn | 1933-0693 1933-0693 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2283316661 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Brain Neoplasms - therapy Cancer Vaccines Glioblastoma - therapy Glioma - therapy Humans Immunotherapy - trends T-Lymphocytes - immunology |
| title | The current state of immunotherapy for gliomas: an eye toward the future |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T16%3A35%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20current%20state%20of%20immunotherapy%20for%20gliomas:%20an%20eye%20toward%20the%20future&rft.jtitle=Journal%20of%20neurosurgery&rft.au=Fecci,%20Peter%20E&rft.date=2019-09-01&rft.volume=131&rft.issue=3&rft.spage=657&rft.pages=657-&rft.issn=1933-0693&rft.eissn=1933-0693&rft_id=info:doi/10.3171/2019.5.JNS181762&rft_dat=%3Cproquest_pubme%3E2283316661%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2283316661&rft_id=info:pmid/31473668&rfr_iscdi=true |